Anti-malarials: Are There Benefits Beyond Mild Disease?
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ohkuma S, Chudzik J, Poole B. The effects of basic substances and acidic ionophores on the digestion of exogenous and endogenous proteins in mouse peritoneal macrophages. J Cell Biol. 1986;102(3):959–66.
Oda K et al. Effects of weakly basic amines on proteolytic processing and terminal glycosylation of secretory proteins in cultured rat hepatocytes. Biochem J. 1986;240(3):739–45.
Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum. 2006;54(10):3068–70.
Blackburn Jr WD et al. Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone. Arthritis Rheum. 1995;38(10):1447–56.
Clark P et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med. 1993;119(11):1067–71.
Davis MJ et al. Should disease-modifying agents be used in mild rheumatoid arthritis? Br J Rheumatol. 1991;30(6):451–4.
Group THS. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. Am J Med. 1995;98(2):156–68.
Singh JA et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–39.
O’Dell JR et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996;334(20):1287–91.
O’Dell JR et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(5):1164–70.
O’Dell JR et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369(4):307–18.
Moreland LW et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012;64(9):2824–35.
Group T.C.H.S. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324(3):150–4. The Canadian Hydroxychloroquine Study Group was the first randomized control trial of the efficacy of hydroxychloroquine in SLE which showed a lower rate of SLE flares and lower rate of severe flares in the hydroxychloroquine users.
Meinao IM et al. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus. 1996;5(3):237–41.
Tsakonas E et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 1998;7(2):80–5.
Costedoat-Chalumeau N et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(10):3284–90.
Barber CE, Geldenhuys L, Hanly JG. Sustained remission of lupus nephritis. Lupus. 2006;15(2):94–101.
Kasitanon N et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006;15(6):366–70.
Shinjo SK et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 2010;62(3):855–62.
Cortes-Hernandez J et al. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford). 2002;41(6):643–50.
Levy RA et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10(6):401–4.
Fessler BJ et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52(5):1473–80.
Molad Y et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus. 2002;11(6):356–61.
Alarcon GS et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168–72.
Ruiz-Irastorza G et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15(9):577–83.
Zhang W et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011;70(4):571–5.
Wallace DJ et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med. 1990;89(3):322–6.
Morris SJ et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2011;63(4):530–4. This observational cohort of 706 RA patients measured levels of total cholesterol, LDL, HDL, and triglycerides in hydroxychloroquine users and found significant decrease in LDL (7.55 mg/dl lower), total cholesterol, LDL/HDL, and total cholesterol/HDL with hydroxychloroquine use after adjusting for steroid and statin use among other variables.
Solomon DH et al. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res (Hoboken). 2014;66(8):1246–51.
Kerr G et al. Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. Arthritis Care Res (Hoboken). 2014;66(11):1619–26.
Wasko MC et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007;298(2):187–93. In the ARAMIS [Arthritis, Rheumatism, and Aging Medical Information Systems] observational trial of 4905 adult RA patients, incident diabetes (self-reported or hypoglycemic medication use) was measured over a 21.5 year period and the authors found that long-term use (>4 years) of hydroxychloroquine was associated with a 77% reduction in the risk of developing diabetes.
Rekedal LR et al. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis Rheum. 2010;62(12):3569–73.
Gerstein HC et al. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas—a randomized trial. Diabetes Res Clin Pract. 2002;55(3):209–19. In this randomized controlled trial of hydroxychloroquine in 135 sulfonylurea-refractory patients with poorly controlled diabetes, the authors measured changes in HbA1c over 18 months and found that hydroxychloroquine decreased HbA1c by 1.02% and improved glucose tolerance.
Quatraro A et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann Intern Med. 1990;112(9):678–81.
Mercer E et al. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther. 2012;14(3):R135.
Madow BPM. Use of antimalarial drugs as “desludging” agents in vascular disease processes. JAMA. 1960;172:1630.
Carter AE, Eban R, Perrett RD. Prevention of postoperative deep venous thrombosis and pulmonary embolism. Br Med J. 1971;1(5744):312–4.
Johnson R, Charnley J. Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty. Clin Orthop Relat Res. 1979;144:174–7.
Jung H et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010;62(3):863–8. This nested case–control study embedded in an inception cohort of 162 patients with SLE showed that anti-malarial use was associated with a 68% reduction in the risk of all thrombovascular events (arterial and venous).
Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum. 1987;30(12):1435–6.
Belizna CC et al. Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmun Rev. 2007;7(1):46–51.
Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus. 1996;5 Suppl 1:S16–22.
Erkan D et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford). 2002;41(8):924–9.
Cecchi E, Ferraris F. Desludging action of Hydroxychloroquine in RA. Acta Rheumatol Scand. 1962;8(1–4):214–21.
Ernst E, Rose M, Lee R. Modification of transoperative changes in blood fluidity by hydroxychloroquine: a possible explanation for the drug’s antithrombotic effect. Pharmatherapeutica. 1983;4(1):48–52.
Kinlough-Rathbone, R. The effects of some other drugs on platelet function. in Platelets, Drugs and Thrombosis: Proceedings of a Symposium Held at McMaster University, Hamilton, Ont., October 16–18, 1972. 1975. S Karger AG.
Jancinova V, Nosál R, Petriková M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb Res. 1994;74(5):495–504.
Nosál R, Jančinová V, Petríková M. Chloroquine inhibits stimulated platelets at the arachidonic acid pathway. Thromb Res. 1995;77(6):531–42.
Edwards MH et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation. 1997;96(12):4380–4.
Espinola RG et al. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost. 2002;87(3):518–22.
Rand JH et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody–β2-glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112(5):1687–95.
Rand JH et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood. 2010;115(11):2292–9.
Poole B, Ohkuma S. Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. J Cell Biol. 1981;90(3):665–9.
Nilsson JR. Does chloroquine, an antimalarial drug, affect autophagy in Tetrahymena pyriformis? J Protozool. 1992;39(1):9–16.
Sotelo J, Briceno E, López-González M. Adding chloroquine to conventional chemotherapy and radiotherapy for glioblastoma multiforme. 2006.
Mukhopadhyay A et al. Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon? Expert Rev Hematol. 2011;4(4):369–71.
Ruiz-Irastorza G et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis. 2007;66(6):815–7.
Sisó A et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus. 2008;17(4):281–8.
Sperber K et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther. 1995;17(4):622–36.
Sperber K et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther. 1997;19(5):913–23.
Paton N, Aboulhab J. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV‐infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. HIV Med. 2005;6(1):13–20.
Malkinson FD, Levitt L. Hydroxychloroquine treatment of porphyria cutanea tarda. Arch Dermatol. 1980;116(10):1147–50.
Ashton RE, Hawk JL, Magnus IA. Low-dose oral chloroquine in the treatment of porphyria cutanea tarda. Br J Dermatol. 1984;111(5):609–13.
Petersen CS, Thomsen K. High-dose hydroxychloroquine treatment of porphyria cutanea tarda. J Am Acad Dermatol. 1992;26(4):614–9.
Woo TY et al. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol. 1984;10(4):592–600.
Quain RD, Werth VP. Management of cutaneous dermatomyositis: current therapeutic options. Am J Clin Dermatol. 2006;7(6):341–51.
Shaffer B, Cahn MM, Levy EJ. Sarcoidosis apparently cured by quinacrine (atabrine) hydrochloride. AMA Arch Dermatol Syphilol. 1953;67(6):640–1.
Modi S, Rosen T. Micropapular cutaneous sarcoidosis: case series successfully managed with hydroxychloroquine sulfate. Cutis. 2008;81(4):351–4.
Levy G et al. Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicenter outpatient practice. Arthritis Rheum. 1997;40(8):1482–6.
Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med. 1983;75(1):40–5.
Rynes RI et al. Ophthalmologic safety of long-term hydroxychloroquine treatment. Arthritis Rheum. 1979;22(8):832–6.
Kahn JB, Haberman ID, Reddy S. Spectral-domain optical coherence tomography as a screening technique for chloroquine and hydroxychloroquine retinal toxicity. Ophthalmic Surg Lasers Imaging. 2011;42(6):493–7.
Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62(6):775–84. Using newer methods to reliably detect early toxicity, before central vision becomes impaired, the authors of this observational study of hydroxhloroquine using rheumatic disease patients found the rate of hydroxychloroquine retinal toxicity to be higher than previously recognized and also reported risk factors for retinopathy.
Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453–60.
Marmor MF et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415–22. The 2011 American Academy of Ophthalmology [AAO] screening guidelines for hydroxychloroquine retinal toxicity recommend baseline assessment using sensitive techniques like Spectral Domain Optical Coherence Tomography [SD-OCT], multi-focal electroretinography [mfERG] or fundus autofluorescence [FAF], plus visual fields and a complete eye examination.
Izmirly PM, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro associated cardiac manifestations of neonatal lupus. Circulation, 2012: p. CIRCULATIONAHA. 111.089268.
Izmirly PM, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Annals of the rheumatic diseases, 2010: p. annrheumdis119263.